An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) management team to participate in virtual fireside chat at JMP Securities Hematology and Oncology Summit. Live webcast available on the company's website.
Positive
None.
Negative
None.
WALTHAM, Mass.--(BUSINESS WIRE)--
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 1:30 PM ET.
A live webcast of the fireside chat will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
When will the virtual fireside chat at the JMP Securities Hematology and Oncology Summit take place for Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)?
The virtual fireside chat will take place on Wednesday, December 6, 2023 at 1:30 PM ET.
Where can I watch the live webcast of the fireside chat for Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)?
The live webcast will be available on the 'Events and Presentations' page in the 'Investors' section of the Company’s website at https://investors.deciphera.com/events-presentations.
How long will the replay of the webcast of the fireside chat be available for Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)?
The replay of the webcast will be archived on the Company’s website for 90 days following the presentation.